Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SUN PHARMA CONCEPT : revenue, balance sheet and financial ratios

SUN PHARMA CONCEPT is a French company founded 6 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in LE GOSIER (97190), this company of category PME shows in 2024 a net income positive of 879€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SUN PHARMA CONCEPT (SIREN 882466717)
Indicator 2024 2020
Revenue N/C N/C
Net income 879 € 581 €
EBITDA N/C N/C
Net margin N/C N/C

Revenue and income statement

In 2024, SUN PHARMA CONCEPT generates positive net income of 879 €. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2020-2024: 581 € -> 879 €.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

879 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 147%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 34%. The balance between equity and debt is satisfactory.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

147.084%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

33.638%

Solvency indicators evolution
SUN PHARMA CONCEPT

Sector positioning

Debt ratio
147.08 2024
2020
2024
Q1: 0.0
Med: 4.27
Q3: 43.96
Watch

In 2024, the debt ratio of SUN PHARMA CONCEPT (147.08) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.

Financial autonomy
33.64% 2024
2020
2024
Q1: 14.64%
Med: 38.36%
Q3: 60.56%
Average +20 pts over 2 years

In 2024, the financial autonomy of SUN PHARMA CONCEPT (33.6%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 591.90. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

591.904

Liquidity indicators evolution
SUN PHARMA CONCEPT

Sector positioning

Liquidity ratio
591.9 2024
2020
2024
Q1: 132.74
Med: 202.27
Q3: 325.9
Excellent +27 pts over 2 years

In 2024, the liquidity ratio of SUN PHARMA CONCEPT (591.90) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Positioning of SUN PHARMA CONCEPT in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Valuation estimate

Based on 124 transactions of similar company sales (all years), the value of SUN PHARMA CONCEPT is estimated at 722 € (range 274€ - 2 637€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
124 transactions
0k€ 0k€ 2k€
722 € Range: 274€ - 2 637€
NAF 5 all-time

Valuation method used

Net Income Multiple
879 € × 0.8x = 722 €
Range: 275€ - 2 637€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare SUN PHARMA CONCEPT with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about SUN PHARMA CONCEPT

What is the revenue of SUN PHARMA CONCEPT ?

The revenue of SUN PHARMA CONCEPT is not publicly disclosed (confidential accounts filed with INPI).

Is SUN PHARMA CONCEPT profitable?

Yes, SUN PHARMA CONCEPT generated a net profit of 879€ in 2024.

Where is the headquarters of SUN PHARMA CONCEPT ?

The headquarters of SUN PHARMA CONCEPT is located in LE GOSIER (97190), in the department Guadeloupe.

Where to find the tax return of SUN PHARMA CONCEPT ?

The tax return of SUN PHARMA CONCEPT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SUN PHARMA CONCEPT operate?

SUN PHARMA CONCEPT operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.